Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...

China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...

Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of Novo Nordisk A/S’ (NYSE ...

Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...